$MDXG
MIMEDX GROUP, INC. Stock $mdxg

$mdxg Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000137633921000032 Filed on April 28, 2021

Income Statement

Concept	2021 Q1	2020 Q4	2020 Q1
Revenue	$59.97M	$68.55M	$61.74M
YoY Change	-2.87%	-10.28%	-7.24%
Cost Of Revenue	$9.641M	$10.82M	$10.03M
YoY Change	-3.83%	-14.87%	35.14%
Gross Profit	$50.33M	$57.73M	$51.71M
YoY Change	-2.68%	-9.36%	-12.56%
Gross Profit Margin	83.92%	84.22%	83.76%
Selling, General & Admin	$45.40M	$48.71M	$46.94M
YoY Change	-3.28%	7.2%	-7.71%
% of Gross Profit	90.22%	84.38%	90.78%
Research & Development	$4.339M	$3.430M	$2.650M
YoY Change	63.74%	26.1%	-8.68%
% of Gross Profit	8.62%	5.94%	5.12%
Depreciation & Amortization	$1.161M	$1.540M	$1.506M
YoY Change	-22.91%	-16.3%	-11.41%
% of Gross Profit	2.31%	2.67%	2.91%
Operating Expenses	$49.74M	$52.39M	$49.59M
YoY Change	0.3%	8.18%	-7.76%
Operating Profit	-$6.852M	$5.340M	-$13.74M
YoY Change	-50.15%	-65.01%	2.47%
Interest Expense	-$1.470M	-$1.510M	-$2.390M
YoY Change	-38.49%	-37.08%	-1238.1%
% of Operating Profit		-28.28%
Other Income/Expense, Net	$0.00	$0.00	$6.000K
YoY Change	-100.0%	-100.0%	-120.69%
Pretax Income	-$8.324M	-$17.60M	-$16.13M
YoY Change	-48.38%	142.42%	21.87%
Income Tax	$58.00K	-$1.020M	-$11.30M
% Of Pretax Income
Net Earnings	-$8.382M	-$16.58M	-$4.821M
YoY Change	73.86%	121.78%	-63.68%
Net Earnings / Revenue	-13.98%	-24.19%	-7.81%
Basic Earnings Per Share	-$0.09	-$0.17	-$0.04
Diluted Earnings Per Share	-$0.09	-$0.17	-$0.04
COMMON SHARES
Basic Shares Outstanding	109.4M shares	111.0M shares	107.5M shares
Diluted Shares Outstanding	109.4M shares		107.5M shares

Balance Sheet

Concept	2021 Q1	2020 Q4	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$84.70M	$95.80M	$53.50M
YoY Change	58.32%	38.64%	88.38%
Cash & Equivalents	$84.75M	$95.81M	$53.50M
Short-Term Investments
Other Short-Term Assets	$3.530M	$3.371M	$5.216M
YoY Change	-32.32%	-44.35%	-28.47%
Inventory	$11.58M	$10.36M	$9.247M
Prepaid Expenses		$5.605M	$5.239M
Receivables	$35.42M	$35.42M	$31.93M
Other Receivables	$10.00M	$10.10M	$10.80M
Total Short-Term Assets	$150.0M	$160.6M	$115.9M
YoY Change	29.39%	30.32%	102.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.04M	$11.44M	$11.83M
YoY Change	-6.67%	-7.23%	-27.75%
Goodwill	$19.98M	$19.98M	$19.98M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$5.918M	$6.004M	$7.581M
YoY Change	-21.94%	-22.8%	-8.57%
Long-Term Investments
YoY Change
Other Assets	$344.0K	$375.0K	$500.0K
YoY Change	-31.2%	-15.35%	-67.43%
Total Long-Term Assets	$40.85M	$41.42M	$43.01M
YoY Change	-5.02%	-5.71%	-14.4%
TOTAL ASSETS
Total Short-Term Assets	$150.0M	$160.6M	$115.9M
Total Long-Term Assets	$40.85M	$41.42M	$43.01M
Total Assets	$190.8M	$202.0M	$158.9M
YoY Change	20.08%	20.86%	47.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.925M	$8.765M	$9.800M
YoY Change	-29.34%	0.63%	-8.33%
Accrued Expenses	$30.68M	$30.46M	$30.66M
YoY Change	0.05%	-5.29%	-14.2%
Deferred Revenue		$554.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$3.750M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$55.41M	$59.16M	$63.70M
YoY Change	-13.01%	-12.12%	-0.93%
LONG-TERM LIABILITIES
Long-Term Debt	$47.80M	$47.70M	$61.64M
YoY Change	-22.45%	-22.95%
Other Long-Term Liabilities	$3.624M	$3.755M	$3.234M
YoY Change	12.06%	6.07%	-31.82%
Total Long-Term Liabilities	$51.42M	$51.45M	$64.87M
YoY Change	-20.73%	-21.38%	1267.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$55.41M	$59.16M	$63.70M
Total Long-Term Liabilities	$51.42M	$51.45M	$64.87M
Total Liabilities	$106.8M	$110.6M	$128.6M
YoY Change	-16.91%	-16.69%	86.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$159.8M	-$151.4M	-$107.0M
YoY Change	49.41%	48.25%	19.07%
Common Stock	$113.0K	$113.0K	$113.0K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$5.091M	$7.449M	$12.58M
YoY Change	-59.52%	-31.07%	-67.09%
Treasury Stock Shares	1.083M shares	1.774M shares	2.163M shares
Shareholders Equity	-$8.051M	-$150.0K	$30.34M
YoY Change
Total Liabilities & Shareholders Equity	$190.8M	$202.0M	$158.9M
YoY Change	20.08%	20.86%	47.9%

Cashflow Statement

Concept	2021 Q1	2020 Q4	2020 Q1
OPERATING ACTIVITIES
Net Income	-$8.382M	-$16.58M	-$4.821M
YoY Change	73.86%	121.78%	-63.68%
Depreciation, Depletion And Amortization	$1.161M	$1.540M	$1.506M
YoY Change	-22.91%	-16.3%	-11.41%
Cash From Operating Activities	-$6.679M	-$10.26M	-$12.28M
YoY Change	-45.62%	-55.62%	-19.52%
INVESTING ACTIVITIES
Capital Expenditures	$1.941M	-$2.280M	-$1.090M
YoY Change	-278.07%	188.61%	32.93%
Acquisitions
YoY Change
Other Investing Activities	$20.00K	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$2.079M	-$2.280M	-$1.086M
YoY Change	91.44%	185.0%	150.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$2.308M	-1.240M	-$2.177M
YoY Change	6.02%	8.77%	108.52%
NET CHANGE
Cash From Operating Activities	-$6.679M	-10.26M	-$12.28M
Cash From Investing Activities	-$2.079M	-2.280M	-$1.086M
Cash From Financing Activities	-$2.308M	-1.240M	-$2.177M
Net Change In Cash	-$11.07M	-13.78M	-$15.54M
YoY Change	-28.81%	-45.01%	-7.13%
FREE CASH FLOW
Cash From Operating Activities	-$6.679M	-$10.26M	-$12.28M
Capital Expenditures	$1.941M	-$2.280M	-$1.090M
Free Cash Flow	-$8.620M	-$7.980M	-$11.19M
YoY Change	-22.97%	-64.26%	-22.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001376339
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-35887
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	MIMEDX GROUP, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2792552
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1775 West Oak Commons Ct NE
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Marietta
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30062
CY2021Q1	dei	City Area Code CityAreaCode	770
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	651-9100
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021Q1	dei	Trading Symbol TradingSymbol	MDXG
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	111718544	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84746000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95812000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35420000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35423000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	11582000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	10361000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4695000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5605000	USD
CY2021Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	9991000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	10045000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	3530000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3371000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	149964000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	160617000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11044000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11437000	USD
CY2021Q1	mdxg	Operating Lease And Financing Lease Right Of Use Asset OperatingLeaseAndFinancingLeaseRightOfUseAsset	3567000	USD
CY2020Q4	mdxg	Operating Lease And Financing Lease Right Of Use Asset OperatingLeaseAndFinancingLeaseRightOfUseAsset	3623000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	19976000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	19976000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5918000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6004000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	344000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	375000	USD
CY2021Q1	us-gaap	Assets Assets	190813000	USD
CY2020Q4	us-gaap	Assets Assets	202032000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6925000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8765000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16153000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18467000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30676000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30460000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1657000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1470000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	55411000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	59162000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	47799000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	47697000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3624000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3755000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	106834000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	110614000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	100000	shares
CY2021Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	100000	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	100000	shares
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	100000	shares
CY2021Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	92030000	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	91568000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	187500000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112703926	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112703926	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111620629	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112703926	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112703926	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110930243	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	113000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	113000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	156733000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	158610000	USD
CY2021Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1083297	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1773683	shares
CY2021Q1	us-gaap	Treasury Stock Value TreasuryStockValue	5091000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	7449000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-159806000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151424000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-8051000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-150000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	190813000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	202032000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59967000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61736000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9641000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10025000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	50326000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	51711000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45404000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46942000	USD
CY2021Q1	mdxg	Investigation Restatementand Related InvestigationRestatementandRelated	7196000	USD
CY2020Q1	mdxg	Investigation Restatementand Related InvestigationRestatementandRelated	15592000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4339000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2650000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	239000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	271000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6852000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13744000	USD
CY2021Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1472000	USD
CY2020Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2387000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8324000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16125000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	58000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11304000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8382000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4821000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9850000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4821000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109401383	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107538509	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109401383	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107538509	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-150000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	462000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3244000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	915000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3216000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8382000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-8051000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	34398000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1915000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	298000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2020Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1451000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4821000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	30339000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8382000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4821000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3244000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3349000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	1161000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	1506000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	239000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	271000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	415000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	668000	USD
CY2021Q1	mdxg	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization	237000	USD
CY2020Q1	mdxg	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization	239000	USD
CY2021Q1	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	17000	USD
CY2020Q1	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	0	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-236000	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-395000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1221000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	143000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-910000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1430000	USD
CY2021Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-54000	USD
CY2020Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	10711000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-319000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-812000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-936000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1046000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-2314000	USD
CY2020Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-4186000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-484000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2845000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-177000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	709000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6679000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12281000	USD
CY2021Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1941000	USD
CY2020Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1011000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	15000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	0	USD
CY2021Q1	mdxg	Paymentsfor Application Costs Patent PaymentsforApplicationCostsPatent	153000	USD
CY2020Q1	mdxg	Paymentsfor Application Costs Patent PaymentsforApplicationCostsPatent	75000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2079000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1086000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	915000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	298000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3216000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1538000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	7000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2021Q1	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	0	USD
CY2020Q1	us-gaap	Repayments Of Medium Term Notes RepaymentsOfMediumTermNotes	937000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2308000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2177000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11066000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15544000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95812000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69069000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84746000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53525000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. Conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported unaudited condensed consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment and intangible assets, estimates regarding asset retirement obligations, estimates for contingent liabilities, the measurement of right-of-use assets and lease liabilities, management’s assessment of the Company’s ability to continue as a going concern, estimates of fair value of share-based payments, and valuation of deferred tax assets.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, the Company has considered the potential effects of the Covid-19 Pandemic with respect to its determinations surrounding impairments, increases in allowances for credit losses, other expenses, and changes in accounting judgments that have or are reasonably likely to have a material impact on the unaudited condensed consolidated financial statements.</span></div>
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	700000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	700000	USD
CY2021Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reportingUnit
CY2019Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	mdxg	Group Purchasing Organization Administrative Feesas Percentof Purchase Volume GroupPurchasingOrganizationAdministrativeFeesasPercentofPurchaseVolume	0.03
CY2021Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	100000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	200000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Cost Incurred To Renew Or Extend FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend	200000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Cost Incurred To Renew Or Extend FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend	100000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	477000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	314000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	6226000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4316000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4879000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5731000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	11582000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	10361000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	41089000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	40935000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30045000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	29498000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11044000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11437000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	1161000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	1506000	USD
CY2021Q1	mdxg	Number Of Subleased Warehouse Spaces NumberOfSubleasedWarehouseSpaces	1	warehouseSpace
CY2021Q1	us-gaap	Sublease Income SubleaseIncome	100000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	335000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	350000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	237000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	239000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	8000	USD
CY2020Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2021Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	USD
CY2020Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3386000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	181000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3623000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	0	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1210000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	42000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1176000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2637000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	140000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2960000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3847000	USD
CY2021Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	182000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4136000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2021Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M24D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2021Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.083
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1151000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	41000	USD
CY2021Q1	mdxg	Lessee Operating Lease And Financing Lease Liability To Be Paid Year One LesseeOperatingLeaseAndFinancingLeaseLiabilityToBePaidYearOne	1621000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	507000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	339000	USD
CY2021Q1	mdxg	Lessee Operating Lease And Financing Lease Liability To Be Paid Remainder Of Fiscal Year LesseeOperatingLeaseAndFinancingLeaseLiabilityToBePaidRemainderOfFiscalYear	1192000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1566000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	55000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	55000	USD
CY2021Q1	mdxg	Lessee Operating Lease And Financing Lease Liability To Be Paid Year Two LesseeOperatingLeaseAndFinancingLeaseLiabilityToBePaidYearTwo	562000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	55000	USD
CY2021Q1	mdxg	Lessee Operating Lease And Financing Lease Liability To Be Paid Year Three LesseeOperatingLeaseAndFinancingLeaseLiabilityToBePaidYearThree	394000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	339000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	5000	USD
CY2021Q1	mdxg	Lessee Operating Lease And Financing Lease Liability To Be Paid Year Four LesseeOperatingLeaseAndFinancingLeaseLiabilityToBePaidYearFour	344000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	339000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q1	mdxg	Lessee Operating Lease And Financing Lease Liability To Be Paid Year Five LesseeOperatingLeaseAndFinancingLeaseLiabilityToBePaidYearFive	339000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	365000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q1	mdxg	Lessee Operating Lease And Financing Lease Liability To Be Paid After Year Five LesseeOperatingLeaseAndFinancingLeaseLiabilityToBePaidAfterYearFive	365000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4606000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	211000	USD
CY2021Q1	mdxg	Lessee Operating Lease And Financing Lease Liability To Be Paid LesseeOperatingLeaseAndFinancingLeaseLiabilityToBePaid	4817000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	759000	USD
CY2021Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	29000	USD
CY2021Q1	mdxg	Lessee Operating Lease And Financing Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseAndFinancingLeaseLiabilityUndiscountedExcessAmount	788000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3847000	USD
CY2021Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	182000	USD
CY2021Q1	mdxg	Operating Lease And Finance Lease Liability OperatingLeaseAndFinanceLeaseLiability	4029000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11291000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7549000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3742000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11285000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7334000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3951000	USD
CY2021Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	13467000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5918000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	13338000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6004000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	239000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	271000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	579000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	692000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	692000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	692000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	280000	USD
CY2021Q1	mdxg	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	807000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3742000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	18812000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	14822000	USD
CY2021Q1	mdxg	Accrued Settlement Costs Current AccruedSettlementCostsCurrent	6850000	USD
CY2020Q4	mdxg	Accrued Settlement Costs Current AccruedSettlementCostsCurrent	9975000	USD
CY2021Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	498000	USD
CY2020Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	688000	USD
CY2021Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2153000	USD
CY2020Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2141000	USD
CY2021Q1	mdxg	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	610000	USD
CY2020Q4	mdxg	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	651000	USD
CY2021Q1	mdxg	Accrued Rebates AccruedRebates	377000	USD
CY2020Q4	mdxg	Accrued Rebates AccruedRebates	886000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1376000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1297000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30676000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30460000	USD
CY2021Q1	mdxg	Temporary Equity Accretedbut Unrecorded Dividends TemporaryEquityAccretedbutUnrecordedDividends	1006000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	50000000	USD
CY2021Q1	mdxg	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	0	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	50000000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8382000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4821000	USD
CY2020Q1	mdxg	Temporary Equity Accretionof Increasingrate Dividend Feature TemporaryEquityAccretionofIncreasingrateDividendFeature	0	USD
CY2021Q1	mdxg	Adjustmentsto Reconcileto Net Income Loss Availableto Common Stockholders AdjustmentstoReconciletoNetIncomeLossAvailabletoCommonStockholders	1468000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109401383	shares
CY2020Q1	mdxg	Temporary Equity Accretedbut Unrecorded Dividends TemporaryEquityAccretedbutUnrecordedDividends	0	USD
CY2021Q1	mdxg	Temporary Equity Accretionof Increasingrate Dividend Feature TemporaryEquityAccretionofIncreasingrateDividendFeature	462000	USD
CY2020Q1	mdxg	Adjustmentsto Reconcileto Net Income Loss Availableto Common Stockholders AdjustmentstoReconciletoNetIncomeLossAvailabletoCommonStockholders	0	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9850000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4821000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107538509	shares
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9850000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4821000	USD
CY2021Q1	mdxg	Adjustmentsto Reconcileto Net Income Loss Availableto Common Stockholders AdjustmentstoReconciletoNetIncomeLossAvailabletoCommonStockholders	1468000	USD
CY2020Q1	mdxg	Adjustmentsto Reconcileto Net Income Loss Availableto Common Stockholders AdjustmentstoReconciletoNetIncomeLossAvailabletoCommonStockholders	0	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9850000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4821000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109401383	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107538509	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30470089	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2706804	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109401383	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107538509	shares
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30470089	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2706804	shares
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.007
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.701
CY2021Q1	mdxg	Effective Income Tax Rate Reconciliation Discrete Items EffectiveIncomeTaxRateReconciliationDiscreteItems	0	USD
CY2020Q1	mdxg	Effective Income Tax Rate Reconciliation Discrete Items EffectiveIncomeTaxRateReconciliationDiscreteItems	11400000	USD
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.007
CY2021Q1	mdxg	Effective Income Tax Rate Reconciliation Discrete Items EffectiveIncomeTaxRateReconciliationDiscreteItems	0	USD
CY2021Q1	mdxg	Effective Income Tax Rate Reconciliation Net Operating Loss Carryforward EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforward	0	USD
CY2021Q1	us-gaap	Interest Paid InterestPaid	1094000	USD
CY2020Q1	us-gaap	Interest Paid InterestPaid	1840000	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	4000	USD
CY2020Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	6000	USD
CY2021Q1	mdxg	Lease Right Of Use Asset And Liability LeaseRightOfUseAssetAndLiability	189000	USD
CY2020Q1	mdxg	Lease Right Of Use Asset And Liability LeaseRightOfUseAssetAndLiability	0	USD
CY2021Q1	mdxg	Notes Receivable For Sale Of Property And Equipment NotesReceivableForSaleOfPropertyAndEquipment	75000	USD
CY2020Q1	mdxg	Notes Receivable For Sale Of Property And Equipment NotesReceivableForSaleOfPropertyAndEquipment	0	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	159000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021Q1	mdxg	Fair Value Of Non Cash Consideration Received For Option Exercise FairValueOfNonCashConsiderationReceivedForOptionExercise	380000	USD
CY2020Q1	mdxg	Fair Value Of Non Cash Consideration Received For Option Exercise FairValueOfNonCashConsiderationReceivedForOptionExercise	0	USD
CY2021Q1	mdxg	Deemed Dividends On Temporary Equity DeemedDividendsOnTemporaryEquity	462000	USD
CY2020Q1	mdxg	Deemed Dividends On Temporary Equity DeemedDividendsOnTemporaryEquity	0	USD
CY2021Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2021Q1	us-gaap	Litigation Reserve LitigationReserve	6900000	USD
CY2021Q1	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	700000	USD
CY2021Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	4400000	USD
CY2019Q1	mdxg	Contingency Loss Number Of Securities Class Actions ContingencyLossNumberOfSecuritiesClassActions	2	securityClassAction
CY2020Q2	mdxg	Contingency Loss Number Of Former Healthcare Providers ContingencyLossNumberOfFormerHealthcareProviders	2	healthcareProvider
CY2020Q1	mdxg	Contingency Loss Number Of Former Clinicians ContingencyLossNumberOfFormerClinicians	2	formerClinician
CY2019Q1	mdxg	Contingency Loss Numberof Former Employees ContingencyLossNumberofFormerEmployees	3	formerEmployee
CY2021Q1	mdxg	Numberof Distribution Channels NumberofDistributionChannels	2	distributionChannel
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59967000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61736000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	36300000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2021Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y8M1D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2025683	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.62
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	352623	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.67
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	50000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.23
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1623060	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.93
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y1M28D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8714632	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1623060	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.93
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y1M28D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8714632	USD

Files In Submission

Name	View Source	Status
0001376339-21-000032-index-headers.html	Edgar Link	pending
0001376339-21-000032-index.html	Edgar Link	pending
0001376339-21-000032.txt	Edgar Link	pending
0001376339-21-000032-xbrl.zip	Edgar Link	pending
exhibit311-2021331.htm	Edgar Link	pending
exhibit312-2021331.htm	Edgar Link	pending
exhibit321-2021331.htm	Edgar Link	pending
exhibit322-2021331.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mdxg-20210331.htm	Edgar Link	pending
mdxg-20210331.xsd	Edgar Link	pending
mdxg-20210331_cal.xml	Edgar Link	unprocessable
mdxg-20210331_def.xml	Edgar Link	unprocessable
mdxg-20210331_htm.xml	Edgar Link	completed
mdxg-20210331_lab.xml	Edgar Link	unprocessable
mdxg-20210331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDXG
MIMEDX GROUP, INC. Stock $mdxg

2021 Q1 Form 10-Q Financial Statement

#000137633921000032 Filed on April 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDXG MIMEDX GROUP, INC. Stock $mdxg

2021 Q1 Form 10-Q Financial Statement

#000137633921000032 Filed on April 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDXG
MIMEDX GROUP, INC. Stock $mdxg